- Home
- REVBW vs IVAC Comparison
REVBW vs IVAC Comparison
Compare REVBW & IVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- IVAC
- Stock Information
- Founded
- REVBW N/A
- IVAC 1990
- Country
- REVBW United States
- IVAC United States
- Employees
- REVBW 9
- IVAC N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- IVAC Industrial Machinery/Components
- Sector
- REVBW Health Care
- IVAC Technology
- Exchange
- REVBW Nasdaq
- IVAC Nasdaq
- Market Cap
- REVBW N/A
- IVAC N/A
- IPO Year
- REVBW 2020
- IVAC 1995
- Fundamental
- Price
- REVBW $0.01
- IVAC $3.37
- Analyst Decision
- REVBW
- IVAC Hold
- Analyst Count
- REVBW 0
- IVAC 1
- Target Price
- REVBW N/A
- IVAC N/A
- AVG Volume (30 Days)
- REVBW N/A
- IVAC 162.8K
- Earning Date
- REVBW N/A
- IVAC 02-03-2025
- Dividend Yield
- REVBW N/A
- IVAC N/A
- EPS Growth
- REVBW N/A
- IVAC N/A
- EPS
- REVBW N/A
- IVAC N/A
- Revenue
- REVBW N/A
- IVAC $65,569,000.00
- Revenue This Year
- REVBW N/A
- IVAC $21.36
- Revenue Next Year
- REVBW N/A
- IVAC N/A
- P/E Ratio
- REVBW N/A
- IVAC N/A
- Revenue Growth
- REVBW N/A
- IVAC 28.52
- 52 Week Low
- REVBW N/A
- IVAC $2.46
- 52 Week High
- REVBW N/A
- IVAC $4.57
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- IVAC 69.41
- Support Level
- REVBW N/A
- IVAC $3.33
- Resistance Level
- REVBW N/A
- IVAC $3.56
- Average True Range (ATR)
- REVBW 0.00
- IVAC 0.16
- MACD
- REVBW 0.00
- IVAC 0.11
- Stochastic Oscillator
- REVBW 0.00
- IVAC 71.87
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).